An FDA advisory panel recently endorsed Grail’s Galleri test, a multi-cancer early detection blood test. The decision marks a step forward for the company’s ambitions. Yet the financial path ahead remains uncertain.
Galleri screens for signals from more than 50 cancer types before symptoms appear. Supporters say such tests could catch disease earlier and save lives. The FDA panel’s backing does not guarantee full approval.
Grail’s business model relies heavily on Medicare coverage. The company needs broad reimbursement to reach profitability. Without it, adoption could stall despite regulatory progress.
Medicare currently does not cover most multi-cancer screening tests. Officials have questioned whether evidence proves the tests extend lives. That gap leaves Grail’s revenue forecasts vulnerable.
Private insurers often follow Medicare’s lead on coverage decisions. A positive national coverage determination could unlock a large market. A negative one could leave Grail dependent on limited cash-pay sales.
Investors have poured money into Grail based on future reimbursement hopes. The stock has swung on regulatory and policy news. Analysts say coverage risk remains the central issue.
The test itself costs around $949 out of pocket. That price limits access for many patients. Widespread coverage would be needed to scale the business.
Grail continues to gather clinical trial data to support its case. More evidence could persuade payers over time. For now, the Medicare question remains unresolved.
